HaitiTuberculosis profile
Population  2014 11 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.1 (1.5–2.9) 20 (14–27)
Mortality (HIV+TB only) 0.77 (0.61–0.95) 7.3 (5.8–9)
Prevalence  (includes HIV+TB) 26 (14–42) 244 (129–395)
Incidence  (includes HIV+TB) 21 (19–24) 200 (177–225)
Incidence (HIV+TB only) 3.7 (3.2–4.3) 35 (31–41)
         
Case detection, all forms (%) 75 (66–85)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.2–3.8) 11 (6.1–17)
MDR-TB cases among notified pulmonary
TB cases
330 (160–500) 120 (66–180)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 9 747   641
Pulmonary, clinically diagnosed 3 521   281
Extrapulmonary 1 541   75
       
Total new and relapse 15 806    
Previously treated, excluding relapses 157    
Total cases notified 15 963    
Among 15 806 new and relapse cases:
1 695 (11%) cases aged under 15 years; male:female ratio: 1.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB   91 (8%) 182
Laboratory-confirmed RR-/MDR-TB cases     91
Patients started on MDR-TB treatment ***     91
TB/HIV 2014 Number (%)
TB patients with known HIV status 13 968 (88)
HIV-positive TB patients 2 588 (19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 630 (63)
HIV-positive TB patients on antiretroviral therapy (ART) 1 396 (54)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 22 038  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (81) 16 557
Previously treated cases registered in 2013 (75) 483
HIV-positive TB cases, all types, registered in 2013 (71) 2 857
RR-/MDR-TB cases started on second-line treatment in 2012 (76) 62
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.1
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 20
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 8.6
% Funded domestically 3%
% Funded internationally 72%
% Unfunded 25%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-30 Data: www.who.int/tb/data